Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products.
暂无分享,去创建一个
Naomi L Kruhlak | R Daniel Benz | Edwin J Matthews | Joseph F Contrera | N. Kruhlak | J. Contrera | R. Benz | E. Matthews | J. F. Contrera
[1] N. Kruhlak,et al. An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. , 2006, Regulatory toxicology and pharmacology : RTP.
[2] N. Kruhlak,et al. An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints. , 2006, Regulatory toxicology and pharmacology : RTP.
[3] N. Kruhlak,et al. In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software. , 2005, Regulatory toxicology and pharmacology : RTP.
[4] A. Bailey,et al. The use of structure-activity relationship analysis in the food contact notification program. , 2005, Regulatory toxicology and pharmacology : RTP.
[5] Joseph F Contrera,et al. QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors. , 2005, Current drug discovery technologies.
[6] Philip Howard,et al. Practical considerations on the use of predictive models for regulatory purposes. , 2005, Environmental science & technology.
[7] N. Kruhlak,et al. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. , 2004, Regulatory toxicology and pharmacology : RTP.
[8] A. Worth,et al. The prospects for using (Q)SARs in a changing political environment--high expectations and a key role for the european commission's joint research centre , 2004, SAR and QSAR in environmental research.
[9] N. Kruhlak,et al. Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. , 2004, Current drug discovery technologies.
[10] R. Snyder,et al. Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules , 2004, Environmental and molecular mutagenesis.
[11] J. Contrera,et al. Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. , 2003, Regulatory toxicology and pharmacology : RTP.
[12] L. Eriksson,et al. Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs. , 2003, Environmental Health Perspectives.
[13] J. Jaworska,et al. Summary of a workshop on regulatory acceptance of (Q)SARs for human health and environmental endpoints. , 2003, Environmental health perspectives.
[14] Paola Gramatica,et al. The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models , 2003 .
[15] John C. Dearden,et al. In silico prediction of drug toxicity , 2003, J. Comput. Aided Mol. Des..
[16] Alan G. E. Wilson,et al. Role of predictive metabolism and toxicity modeling in drug discovery--a summary of some recent advancements. , 2003, Current opinion in drug discovery & development.
[17] G M Pearl,et al. Integration of computational analysis as a sentinel tool in toxicological assessments. , 2001, Current topics in medicinal chemistry.
[18] L. Hall,et al. Molecular Structure Description: The Electrotopological State , 1999 .
[19] J. Contrera,et al. A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. , 1998, Regulatory toxicology and pharmacology : RTP.
[20] John M. Barnard,et al. Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..
[21] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[22] E. Zeiger,et al. Handbook of Carcinogenic Potency and Genotoxicity Databases , 1996 .
[23] P. Wagner,et al. The new chemicals process at the Environmental Protection Agency (EPA): structure-activity relationships for hazard identification and risk assessment. , 1995, Toxicology letters.
[24] M C Cimino,et al. Availability of the GENE-TOX database on the National Library of Medicine TOXNET system. , 1993, Environmental and molecular mutagenesis.
[25] J. Selkirk. Compendium of Abstracts from Long-Term Cancer Studies Reported by the National Toxicology Program from 1976 to 1992 , 1993 .
[26] B. Ames,et al. The fifth plot of the Carcinogenic Potency Database: results of animal bioassays published in the general literature through 1988 and by the National Toxicology Program through 1989. , 1993, Environmental health perspectives.
[27] R. Tennant,et al. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. , 1991, Mutation research.
[28] J. Reynolds. Martindale: the Extra Pharmacopoeia. 29th edition. , 1989 .